Trade Name(s)

  • Danyelza

Ther. Class.


none assigned

Pharm. Class.

monoclonal antibodies


Relapsed or refractory high-risk neuroblastoma in the bone or bone marrow in patients who have demonstrated a partial response, minor response, or stable disease to prior therapy (in combination with granulocyte-macrophage colony-stimulating factor [GM-CSF]) .


Acts as a glycolipid disialoganglioside (GD2)-binding monoclonal antibody that binds to specific cells in the CNS and peripheral nerves, inducing cell lysis through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Therapeutic Effect(s):

Decreased progression of neuroblastoma.


Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism and Excretion: Metabolized into small peptides.

Half-life: 8.2 days.

TIME/ACTION PROFILE (plasma concentrations)

IVunknownend of infusionunknown


Contraindicated in:

  • Severe hypersensitivity
  • Uncontrolled hypertension
  • OB:   Pregnancy (may cause fetal harm)
  • Lactation:  Lactation.

Use Cautiously in:

  • Rep:   Women of reproductive potential
  • Pedi:   Children <1 yr (safety and effectiveness not established).

Adverse Reactions/Side Effects

CV: hypertension, peripheral edema, tachycardia

Derm: ↑ sweating, erythema multiforme, urticaria

EENT: blurred vision, impaired vision, mydriasis, photophobia, rhinorrhea, unequal pupils

Endo: hyperglycemia, hypoglycemia

F and E: hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia

GI: ↑ liver enzymes, constipation, diarrhea, hypoalbuminemia, nausea, vomiting

GU: urinary retention

Hemat: anemia, lymphocytopenia, neutropenia, thrombocytopenia

Local: injection site reaction

Metabolic: ↓ appetite, ↓ weight

Neuro: anxiety, fatigue, headache, irritability, neuropathic pain, peripheral neuropathy, sedation, POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES), transverse myelitis

Resp: cough


* CAPITALS indicate life-threatening.
Underline indicate most frequent.



None reported.


IV (Adults): 3 mg/kg/day (max = 150 mg/day) on Days 1, 3, and 5 of each treatment cycle. Repeat treatment cycle every 4 wk until complete response or partial response, then repeat treatment cycle every 4 wk for 5 cycles. Subsequent treatment cycles may be repeated every 8 wk. Discontinue treatment if disease progression or unacceptable toxicity occurs.


Solution for injection: 4 mg/mL


  • Monitor closely for signs and symptoms of infusion reactions and hypersensitivity reactions (facial or lip swelling, urticaria, difficulty breathing) during and for at least 2 hrs following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  If Grade 2 infusion reaction (therapy or infusion interruption indicated but responds promptly to symptomatic treatment [antihistamines, NSAIDs, opioids, IV fluids]; prophylactic medications indicated for ≤24 hrs occurs,  reduce naxitamab infusion rate to 50% of previous rate and monitor closely until recovery to Grade ≤ 1. Increase infusion rate gradually to rate prior to the event as tolerated.  If Grade 3 reaction (prolonged [not rapidly responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae occurs,  immediately interrupt infusion and monitor closely until recovery to Grade ≤ 2. Resume infusion at 50% of rate prior to the event and increase infusion rate gradually to infusion rate prior to the event as tolerated. Permanently discontinue naxitamab in patients not responding to medical intervention.  If Grade 4 infusion-related reaction (life-threatening consequences: urgent intervention indicated or Grade 3 or 4 anaphylaxis occurs, permanently discontinue naxitamab.
  • Assess for pain (abdominal pain, bone pain, neck pain, extremity pain) during and following each infusion. Usually begins during infusion and lasts <1 day.  If Grade 3 pain (unresponsive to maximum supportive measures) occurs,  permanently discontinue naxitamab.
  • Monitor BP before starting, during infusion and at least daily on Days 1–8 of each cycle. Do not start therapy if patient has uncontrolled hypertension.  If Grade 3 hypertension occurs,  hold naxitamab or pause infusion until recovery to ≤Grade 2. Resume infusion at 50% of prior rate; if tolerated without recurrence of symptoms, gradually increase to rate prior to onset of symptoms. Permanently discontinue naxitamab in patients not responding to medical intervention or if Grade 4 hypertension occurs.
  • Assess for symptoms of PRES or transverse myelitis (paresthesia, loss of reflexes without pain, loss of function, sensory loss).  If symptoms of PRES or transverse myelitis occur, permanently discontinue naxitamab.
  • Monitor for symptoms of peripheral neuropathy (numbness, pain, burning, paresthesia in extremities) during therapy. Usually begins during infusion and last 5–6 days.  If ≥Grade 2 motor neuropathy or Grade 3 or 4 sensory neuropathy occurs,  permanently discontinue naxitamab.
  • Monitor for signs and symptoms of neurological disorders of the eye (unequal pupils, blurred vision, accommodation disorder, mydriasis, visual impairment, photophobia) during therapy. May last around 17 days.  If Grade 2 to 4 resulting in decreased visual acuity or limiting activities of daily living occurs,  hold naxitamab until resolution. If resolved resume naxitamab at 50% of prior dose; if tolerated without recurrence of symptoms, gradually increase to dose prior to onset of symptoms. Permanently discontinue naxitamab if not resolved within 2 wks or upon recurrence or if subtotal or total vision loss occurs.
  • Monitor for prolonged urinary retention.  If persists following discontinuation of opioids, permanently discontinue naxitamab.

Lab Test Considerations:

Verify negative pregnancy test before starting therapy.

  • May cause decreased serum potassium, sodium, and albumin. May cause increased AST and ALT.
  • May cause decreased lymphocytes, neutrophils, hemoglobin, and platelet count.


  • Premedications and Supportive Medications: Administer sargramostim (GM-CSF) 250 mcg/m2  /day SUBQ, beginning 5 days before naxitamab infusion, then administer 500 mcg/m2  /day Days 1–5. Administer at least 1 hr before naxitamab infusion on Days 1, 3, and 5.
  • Pain Management Prior to and During Infusion: Administer prophylactic medication for neuropathic pain (gabapentin) each day starting 5 days before 1st infusion of naxitamab and through Day 7.
  • Administer oral opioids 45–60 min before starting each infusion of naxitamab and administer additional IV opioids as needed for breakthrough pain during infusion.
  • Consider use of ketamine for pain that is not adequately controlled by opioids.
  • Premedication to Reduce Risk of Infusion-Related Reactions and Nausea/Vomiting: Administer IV corticosteroids (methylprednisolone 2 mg/kg with maximum dose of 80 mg or equivalent corticosteroid dose) 30 min to 2 hr before 1st infusion of naxitamab. Administer corticosteroid premedication for subsequent infusions if severe infusion reaction occurred with previous infusion or during the previous cycle.
  • Administer an antihistamine, an H2  antagonist, acetaminophen and an antiemetic 30 min before each infusion.
  • If a naxitamab dose is missed, administer missed dose the following week by Day 10. Administer sargramostim (GM-CSF) 500 mcg/m2 /day on 1st day of infusion, and on the day before and on the day of the 2nd and 3rd infusion, respectively (total of 5 days with 500 mcg /m2 /day).

IV Administration

  • Intermittent Infusion:   Dilution:  Add appropriate quantities of 5% Albumin (Human), and 0.9% NaCl, to an empty, sterile IV infusion bag large enough to hold the volume needed for dose (see manufacturer's instructions). Allow for 5-10 min of passive mixing. Withdraw the required dose of naxitamab and inject into infusion bag containing the 5% Albumin (Human) and 0.9% NaCl. Discard any unused portion of naxitamab left in vial. Solution is clear to slightly opalescent and colorless to slightly yellow solution; discard solutions that are cloudy, discolored, or contain particulate matter. Solution is stable for up to 8 hr at room temperature or 24 hr if refrigerated. Once removed from refrigeration, infuse within 8 hr.
  • Rate: Infuse 1st infusion over 60 min. Infuse subsequent infusions over 30–60 min as tolerated. Observe patient for a minimum of 2 hrs following each infusion.

Patient/Family Teaching

  • Explain purpose of naxitamab to patient. Advise patient to read  Patient Information  before starting therapy and periodically during therapy in case of changes.
  • Advise patient to notify health care professional immediately if signs and symptoms of infusion related reactions (swelling of face, eyes, lips, mouth, or tongue; itching; redness on face [flushing]; rash; hives; trouble breathing; cough; wheezing; noisy high-pitched breathing; feeling faint or dizziness [low blood pressure]) occur.
  • Advise patient to notify health care professional if signs and symptoms of severe pain (severe pain in abdomen, bones, neck, legs, arms); inflammation of spinal cord (weakness in legs or arms; bladder and bowel problems; pain in back, legs, or abdomen; numbness; tingling; burning sensation); PRES (severe headache; vision changes; changes in mental status [confusion, disorientation, decreased alertness], difficulty speaking; weakness in arms or legs; seizures); numbness, tingling, or burning sensation in the arms or legs; nervous system problems of the eye (unequal pupil size, blurred vision, trouble focusing your eyes, dilated pupils, decreased ability to see, sensitivity to light) or problems urinating or emptying your bladder occur.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking Rx, OTC, or herbal products.
  • Rep:  May cause fetal harm. Advise female of reproductive potential to use effective contraception and avoid breastfeeding during and for 2 mo after last dose of naxitamab.

Evaluation/Desired Outcomes

Decreased progression of neuroblastoma.